WHO news

The World Health Organization is taking part in the Paris Olympics in multiple fields, supporting the International Olympic Committee (IOC) and France to help make the world’s leading sport spectacle, which officially starts this Friday, healthy and safe for spectators and athletes alike.

Sixteen people from Gaza with complicated medical conditions will arrive in Spain today to receive care there, through an evacuation process involving the World Health Organization (WHO) and multiple partners. Fifteen of them are children, ranging in age from 3 to 17 years old. The mother of one of the children will also be treated in Spain. The patients had been in hospital in Egypt for the past several months, after evacuating from Gaza. They are a small portion of the thousands of other children and adults who need access to specialized medical care outside of Gaza.

“These very sick children will be getting the care they need thanks to cooperation between several partners and countries,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “We are immensely grateful for the support and facilitation provided by Egypt and Spain. We encourage other countries who have the capacity and medical facilities to welcome people who, through no fault of their own, are caught in the grips of this war.”

Thirteen of the children have complex injuries, one has a chronic heart condition, and one is living with cancer. The children, who are accompanied by 25 family members and other caregivers, have been in Egypt since before 6 May, after which evacuations became almost impossible with the closure of the Rafah crossing. Only 23 people have been evacuated since then, via the Kerem Shalom crossing.

Since October 2023, around 5000 people have been evacuated for treatment outside Gaza, with over 80% receiving care in Egypt, Qatar and the United Arab Emirates. Another 10 000 still need to be evacuated.

“These children are just the tip of the iceberg. Thousands of people of all ages still remain in Gaza who need to be medically evacuated and are at risk of dying if they are unable to quickly access the advanced medical care they need,” said Dr Hanan Balkhy, WHO Regional Director for the Eastern Mediterranean. “Patients who need evacuation outside of the Gaza Strip must be able to exit, preferably to the West Bank, including East Jerusalem, but also to Egypt or Jordan and then onwards.”

Today’s evacuation to Spain was supported through the EU Civil Protection Mechanism in partnership with WHO. The Palestine Children’s Relief Fund facilitated the patients’ documentation and evacuation approvals. The Government of Egypt supported their care while they were there, and Spain is providing similar support. The children will be treated at various hospitals across Spain.   

WHO is encouraging other countries to follow this example.

“We are truly thankful to Spain, a WHO/Europe Member State, for having responded so willingly to our request to accept several children from Gaza for critical treatment, a template for other countries to follow,” said Dr Hans Henri P. Kluge, WHO Regional Director for Europe. “Gracias, Prime Minister Pedro Sanchez, Health Minister Monica Garcia, and all who have made this possible. Indeed, ‘to save one child, one life, is to save humankind’ is a concept recognizing the interconnectedness of all humanity.”

WHO appeals for the establishment of multiple medical evacuation corridors to ensure sustained, organized, safe and timely passage of patients via all possible routes, including Rafah and Kerem Shalom. Of utmost urgency is the restoration of medical evacuations from Gaza to the West Bank, including East Jerusalem, where hospitals are ready to receive patients. Patients must also be facilitated to be transferred to Egypt and Jordan, and from there to other countries when needed.

“The solidarity of the host countries is a bright spot in a war that has had so many moments of tragedy,” said Dr Tedros. “The fact that severely ill people are receiving needed medical care should not be headline news, but routine global cooperation.” 

WHO once again calls for the end of the war, as peace is ultimately the best path to health.

Around 733 million people faced hunger in 2023, equivalent to one in eleven people globally and one in five in Africa, according to the latest State of Food Security and Nutrition in the World (SOFI) report published today by five United Nations specialized agencies.

Despite progress made in reducing HIV infections and AIDS-related deaths among children, a new report released today by the Global Alliance for Ending AIDS in Children by 2030 shows that an urgent scale up of HIV services in countries worst affected by the pandemic is required to end AIDS by 2030.

Joint statement by UNICEF Executive Director, Catherine Russell, UNFPA Executive Director, Natalia Kanem, WHO Director-General, Dr Tedros Adhanom Ghebreyesus, UN Women Executive Director, Sima Bahous, and UN High Commissioner for Human Rights, Volker Türk  

“Following the vote today by the National Assembly of The Gambia, we commend the country’s decision to uphold the ban on Female Genital Mutilation (FGM), reaffirming its commitments to human rights, gender equality, and protecting the health and well-being of girls and women. 

“FGM involves cutting or removing some or all of the external female genitalia. Mostly carried out on infants and young girls, it can inflict severe immediate and long-term physical and psychological damage, including infection, later childbearing complications, and post-traumatic stress disorder.

“The Women’s (Amendment) Act, 2015 – a pivotal milestone in advancing gender equality – is the culmination of years of advocacy, community engagement, and education aimed at eradicating this harmful practice and meeting the Sustainable Development Goal targets (5.3). It is, therefore, crucial that these legal protections remain in place. 

“The decision to maintain the FGM ban aligns with The Gambia's international and regional commitments to prevent harmful practices against girls and women, consistent with the Convention on the Rights of the Child (CRC), the Convention on the Elimination of All Forms of Discrimination Against Women (CEDAW), the African Charter on the Rights and Welfare of the Child, and the Maputo Protocol protecting African women’s rights.

“In addition to recognizing this critical decision by the national parliament, we commend the tireless efforts of survivors, activists, civil society organizations, and faith-based groups working to end FGM. Upholding the ban supports these grassroots initiatives, which are pivotal in ending all forms of violence, including harmful practices, against girls and women and delivering a safer and healthier future for girls and women in The Gambia and elsewhere.  

“The fragility of progress to end FGM cannot be overstated. Assaults on women’s and girls’ rights in countries around the globe have meant that hard-won gains are in danger of being lost. In some countries, advancements have stalled or reversed due pushback against girls’ and women's rights, instability, and conflict, disrupting services and prevention programmes. 

“That is why legislative bans on FGM, while a crucial foundation for interventions, cannot alone end FGM. Today, more than 73 per cent of girls and women aged 15 to 49 in the country have already undergone this harmful practice, with many subjected to it before their fifth birthday.  

“Recent months have emphasized the need for continued advocacy to advance gender equality, end violence against girls and women, and secure the gains made to accelerate progress to end FGM. It also underscores the importance of engaging with communities and grassroots organizations, working with traditional, political, and religious leaders, training health workers, and raising awareness effectively on the harms caused by the practice.  

“Supporting survivors of FGM remains as urgent as ever. Many suffer from long-term physical and psychological harm that can result from the procedure, and need comprehensive medical and psychological care to heal from the scars inflicted by this harmful practice.   

“We remain steadfast in our commitment to support the government, civil society, and communities in The Gambia in the fight against FGM. Together, we must not rest until we ensure that all girls and women can live free from violence and harmful practices and that their rights, bodily integrity, and dignity are upheld." 

 

 

About UNICEF 
UNICEF works in some of the world's toughest places, to reach the world's most disadvantaged children. Across more than 190 countries and territories, we work for every child, everywhere, to build a better world for everyone. 

For more information about UNICEF and its work, visit: www.unicef.org  
Follow UNICEF on Twitter, Facebook, Instagram and YouTube 

  

About UNFPA 

UNFPA is the United Nations sexual and reproductive health agency. UNFPA's mission is to deliver a world where every pregnancy is wanted, every childbirth is safe and every young person's potential is fulfilled. UNFPA calls for the realization of reproductive rights for all and supports access to a wide range of sexual and reproductive health services, including voluntary family planning, quality maternal health care and comprehensive sexuality education. 

For more information about UNFPA and its work, visit: www.unfpa.org  

 
About WHO 
Dedicated to the well-being of all people and guided by science, the World Health Organization leads and champions global efforts to give everyone, everywhere an equal chance at a safe and healthy life. We are the UN agency for health that connects nations, partners and people on the front lines in 150+ locations – leading the world’s response to health emergencies, preventing disease, addressing the root causes of health issues and expanding access to medicines and health care. Our mission is to promote health, keep the world safe and serve the vulnerable. www.who.int    

  

About UN Women 

UN Women is the UN organization dedicated to gender equality and the empowerment of women. A global champion for women and girls, UN Women was established to accelerate progress on meeting their needs worldwide. For more information, visit www.unwomen.org. UN Women, 220 East 42nd Street, New York, NY 10017, New York. Tel: +1 646 781-4400. Fax: +1 646 781-4496. For more information, visit www.unwomen.org. 

 

About UN Human Rights
The Office of the High Commissioner for Human Rights (UN Human Rights) is the leading UN entity on human rights. We represent the world's commitment to the promotion and protection of the full range of human rights and freedoms set out in the Universal Declaration of Human Rights.

For more information, visit: www.ohchr.org

 

Global childhood immunization coverage stalled in 2023, leaving 2.7 million additional children un- and under-vaccinated compared to pre-pandemic levels in 2019, according to data published today by the World Health Organization (WHO) and UNICEF.

The latest WHO and UNICEF estimates of national immunization coverage (WUENIC) – which provide the world’s largest and most comprehensive dataset on immunization trends for vaccinations against 14 diseases – underscore the need for ongoing catch-up, recovery and system-strengthening efforts.

“The latest trends demonstrate that many countries continue to miss far too many children,” said UNICEF Executive Director Catherine Russell. “Closing the immunization gap requires a global effort, with governments, partners, and local leaders investing in primary healthcare and community workers to ensure every child gets vaccinated, and that overall healthcare is strengthened.”

According to the findings, the number of children who received three doses of the vaccine against diphtheria, tetanus and pertussis (DTP) in 2023 – a key marker for global immunization coverage – stalled at 84% (108 million). However, the number of children who did not receive a single dose of the vaccine increased from 13.9 million in 2022 to 14.5 million in 2023.

More than half of unvaccinated children live in the 31 countries with fragile, conflict-affected and vulnerable settings, where children are especially vulnerable to preventable diseases because of disruptions and lack of access to security, nutrition, and health services.

Additionally, 6.5 million children did not complete their third dose of the DTP vaccine, which is necessary to achieve disease protection in infancy and early childhood.

These trends, which show that global immunization coverage has remained largely unchanged since 2022 and – more alarmingly – has still not returned to 2019 levels, reflect ongoing challenges with disruptions in healthcare services, logistical challenges, vaccine hesitancy and inequities in access to services.

Low vaccine coverage already driving measles outbreaks

The data further show that vaccination rates against the deadly measles disease stalled, leaving nearly 35 million children with no or only partial protection.

In 2023, only 83% of children worldwide received their first dose of the measles vaccine through routine health services, while the number of children receiving their second dose modestly increased from the previous year, reaching 74% of children. These figures fall short of the 95% coverage needed to prevent outbreaks, avert unnecessary disease and deaths, and achieve measles elimination goals.

Over the last five years, measles outbreaks hit 103 countries – home to roughly three-quarters of the world’s infants. Low vaccine coverage (80% or less) was a major factor. In contrast, 91 countries with strong measles vaccine coverage did not experience outbreaks.

“Measles outbreaks are the canary in the coalmine, exposing and exploiting gaps in immunization and hitting the most vulnerable first,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “This is a solvable problem. Measles vaccine is cheap and can be delivered even in the most difficult places. WHO is committed to working with all our partners to support countries to close these gaps and protect the most at-risk children as quickly as possible.”

Global HPV vaccine coverage among girls increased substantially

The new data also highlight some brighter spots in immunization coverage. The steady introduction of new and under-utilized vaccines, including for human papillomavirus (HPV), meningitis, pneumococcal, polio and rotavirus disease, continue to expand the breadth of protection, particularly in the 57 countries supported by Gavi, the Vaccine Alliance.  

For example, the share of adolescent girls globally who received at least 1 dose of the HPV vaccine, which provides protection against cervical cancer, increased from 20% in 2022 to 27% in 2023. This was largely driven by strong introductions in Gavi-supported countries, such as Bangladesh, Indonesia, and Nigeria. The use of the single-dose HPV vaccine schedule also helped boost vaccine coverage.

"The HPV vaccine is one of the most impactful vaccines in Gavi’s portfolio, and it is incredibly heartening that it is now reaching more girls than ever before,” said Dr Sania Nishtar, CEO of Gavi, the Vaccine Alliance. “With vaccines now available to over 50% of eligible girls in African countries, we have much work to be done, but today we can see we have a clear pathway to eliminating this terrible disease.”  

However, HPV vaccine coverage is well below the 90% target to eliminate cervical cancer as a public health problem, reaching only 56% of adolescent girls in high-income countries and 23% in low- and middle-income countries. 

A recent poll of over 400 000 users of UNICEF’s digital platform for young people, U-Report, revealed that over 75% are unaware or unsure of what HPV is, underscoring the need for better vaccine accessibility and public awareness. When informed about the virus, its link to cancers, and the existence of a vaccine, 52% of respondents indicated they want to receive the HPV vaccine but are hindered by financial constraints (41%) and lack of availability (34%).

Robust local action needed to reach everyone, everywhere with vaccines

While there’s been modest progress in some regions, including the African region and low-income countries, the latest estimates highlight the need to accelerate efforts to meet the Immunization Agenda 2030 (IA2030) targets of 90% coverage, and no more than 6.5 million ‘zero-dose’ children globally by 2030.

The IA2030 Partnership Council calls for increased investment in innovation and ongoing collaboration. The council also recommends partners step up their support for country leadership to improve routine immunization as part of their integrated primary health care programmes, backed by robust political support, community leadership, and sustainable funding.   

 

 

Notes to editorsAbout the data

Based on country-reported data, the WHO and UNICEF estimates of national immunization coverage (WUENIC) provide the world’s largest and most comprehensive dataset on immunization trends for vaccinations against 14 diseases given through regular health systems - normally at clinics, community centres, outreach services, or health worker visits. For 2023, data were provided from 185 countries.

About the Immunization Agenda 2030 (IA2030)

The IA2030 is a global strategy endorsed by the World Health Assembly aiming to ensure everyone, everywhere, at every age benefits from vaccines for improved health and well-being by 2030. It focuses on increasing vaccine coverage, equity, sustainability and pandemic preparedness while promoting life-course immunization and integrating immunization with other health services.

About WHO

Dedicated to the health and well-being of all people and guided by science, the World Health Organization leads and champions global efforts to give everyone, everywhere, an equal chance at a safe and healthy life. We are the UN agency for health that connects nations, partners and people on the front lines in 150+ locations – leading the world’s response to health emergencies, preventing disease, addressing the root causes of health issues and expanding access to medicines and health care. Our mission is to promote health, keep the world safe and serve the vulnerable. 

About UNICEF UNICEF works in some of the world's toughest places, to reach the world's most disadvantaged children. Across more than 190 countries and territories, we work for every child, everywhere, to build a better world for everyone.

For more information about UNICEF and its work, visit: www.unicef.org Follow UNICEF on Twitter, Facebook, Instagram and YouTube.

 

The World Health Organization has released "The Role of Parliaments and Parliamentarians in Strengthening Health Security Preparedness", an online training course. This essential resource aims to equip parliamentarians with the knowledge and tools necessary to enhance global health security efforts.

The World Health Organization (WHO) has prequalified the first hepatitis C virus (HCV) self-test which can provide a critical support in expanding access to testing and diagnosis, accelerating global efforts to eliminate hepatitis C.

World Health Organization (WHO) has introduced an online platform called MeDevIS (Medical Devices Information System), the first global open access clearing house for information on medical devices. It is designed to support governments, regulators and users in their decision-making on selection, procurement and use of medical devices for diagnostics, testing and treatment of diseases and health conditions.

The MeDevIS platform includes 2301 types of medical devices used for a broad-ranging health issues, including reproductive, maternal, newborn and child health, noncommunicable diseases such as cancer, cardiovascular diseases, diabetes as well as infectious diseases such as COVID-19.

“The number of medical technologies used in health care is growing, as is their complexity, which can make it challenging for health care practitioners and patients to navigate,” said Dr Yukiko Nakatani, WHO Assistant Director-General for Access to Medicines and Health Products. “We aim to provide a one stop shop of international information, which can be invaluable for those making decisions on life-saving medical technologies, especially in resource-limited settings, and to improve access”.

There are over 10 000 different medical devices that are being used for protection, prevention, diagnostics, treatment or rehabilitation of health issues globally. These include multiple simple and complex medical technologies ranging from pulse oximeters, digital thermometers, single-use syringes and medical masks to various diagnostic laboratory tests and other medical equipment including electrocardiograms, endoscopes, all imaging radiology technologies, and technologies used for treatments such as hemodialysis units and defibrillators, implantable prothesis, cardiac stents and complex radiotherapy equipment.

However, currently there are multiple, separate sources of information produced by major international organizations, regulatory bodies, and donor agencies, making it difficult for users to discern and utilize the most reliable data. In MeDevIS, users can check devices they require, including type, level of health care systems to support the device (such as community or specialized hospitals), scope of the device, and infrastructure required, among other categories.

MeDevIS replaces paper-based literature search across multiple publications with non-standard device names which can add to the complexity. Along with providing a single platform, MedevIS also aims to help make the naming of the medical devices simpler.

MeDevIS references two international naming systems for medical devices - the European Medical Device Nomenclature (EMDN), mostly used in European countries for registration in the European database, and the Global Medical Device Nomenclature (GMDN) used in regulatory agencies in Australia, Canada, the United Kingdom and the USA and other Member States. The naming systems include coding and definitions and can be used in every country to facilitate registration for regulatory approval, procurement and supply, inventories in health facilities, tracking and pricing.

“The MeDevIS platform can be useful for national policy-makers to develop or update their own national lists for procurement of health technologies and devices and can contribute to the progress towards universal health coverage,” said Dr Deus Mubangizi, WHO Director for Health Products Policy and Standards in the Access to Medicines and Health Products Division. “It can also help agencies in health insurance and reimbursement policies for patients.”

This is the first time WHO has developed such a global repository on medical devices, based on its experience with the WHO Priority Medical Devices List (MDL), which itself was based on the experience of creating the WHO Essential Medicines List (EML). Approaching its 50th anniversary in 2025, EML is regarded as a pillar of public health in countries across the world, supporting health progress and touching billions of lives.

WHO will be continually improving the MeDevIS platform, engaging multiple stakeholders and partners and expanding it with additional technologies and devices used in various health areas, including in pandemic and emergency settings.

Note to Editors:

The MeDevIS platform became operational in March 2024 for the purpose of consultation with WHO Member States. Following the consultation, it is being publicly released via an online webinar “Nomenclature of medical devices: EMDN & GMDN” on 8 July 2024 at 14:00-15:00 CEST.

WHO recently issued updated guidance for national authorities and biomedical laboratories to manage biological risks.

Laboratories are essential components of health systems, critical for patient diagnosis and rapid clinical care, disease surveillance, pathogen characterization, and research and development for treatments and vaccines. Appropriately designed and equipped facilities, trained staff, evidence-based risk mitigating measures, transparent reporting and layered oversight mechanisms will safeguard the workforce and the community from pathogenic microorganisms and toxins.

New updates in the guidance include the strengthening of cybersecurity measures and handling of confidential information such as patient records; reducing risks from new technologies, including those related to genetic modification and manipulation of pathogens, and artificial intelligence (AI); and advice on keeping laboratories safe and secure during emergencies like wars, civil unrest, and disasters from natural hazards.

WHO’s updated laboratory biosecurity guidance helps all countries, especially those lacking regulations, establish or strengthen frameworks for handling high-consequence pathogens. It highlights the importance of strong institutional governance through an Institutional Biosafety Committee with national oversight.

The updated guidance provides best practices and recommendations, while encouraging Member States to adopt a risk-based approach, stipulated in the resolution on ‘Strengthening laboratory biological risk management’ adopted at the World Health Assembly this year.

The guidance was developed in consultation with wide range of stakeholders including WHO collaborating centres and technical advisory groups, in particular, the WHO Technical Advisory Group on Biosafety (TAG-B).  

By promoting engagement and commitment from institutions and national authorities, the guidance mitigates risks associated with high-consequence pathogens and research work. These measures aim to safeguard communities from misuse and release of biological materials, be it intentional or inadvertent, all while allowing legitimate biomedical research to continue.

 

The World Health Organization (WHO) recommends a comprehensive set of tobacco cessation interventions, including behavioural support delivered by health-care providers, digital cessation interventions and pharmacological treatments in a first guideline on tobacco cessation.

The guideline focuses on helping the more than 750 million tobacco users who want to quit all forms of tobacco. The recommendations are relevant for all adults seeking to quit various tobacco products, including cigarettes, waterpipes, smokeless tobacco products, cigars, roll-your-own tobacco, and heated tobacco products (HTPs).

“This guideline marks a crucial milestone in our global battle against these dangerous products," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "It empowers countries with the essential tools to effectively support individuals in quitting tobacco and alleviate the global burden of tobacco-related diseases.”

Over 60% of the world's 1.25 billion tobacco users – more than 750 million people – wish to quit, yet 70% lack access to effective cessation services. This gap exists due to challenges faced by health systems, including resource limitations.

“The immense struggle that people face when trying to quit smoking cannot be overstated. We need to deeply appreciate the strength it takes and the suffering endured by individuals and their loved ones to overcome this addiction,” said Dr Rüdiger Krech, Director of Health Promotion at WHO. ”These guidelines are designed to help communities and governments provide the best possible support and assistance for those on this challenging journey.”

Effective therapies for quitting tobacco

Combining pharmacotherapy with behavioural interventions significantly increases quitting success rates. Countries are encouraged to provide these treatments at no or reduced cost to improve accessibility, particularly in low- and middle-income countries.

WHO recommends varenicline, Nicotine Replacement Therapy (NRT), bupropion, and cytisine as effective treatments for tobacco cessation.

In 2023, WHO initiated a prequalification procedure for medicinal products against disorders caused by tobacco use to improve global access to recommended tobacco cessation medications. In April 2024, Kenvue’s nicotine gum and patch became the first WHO-prequalified NRT products.

WHO recommends behavioural interventions, including brief health worker counselling (30 seconds to 3 minutes) offered routinely in health-care settings, alongside more intensive behavioural support (individual, group, or phone counselling) for interested users. Additionally, digital interventions such as text messaging, smartphone apps, and internet programmes can be used as adjuncts or self-management tools.

WHO encourages health-care providers, policy-makers, and stakeholders to adopt and implement this guideline to promote tobacco cessation and improve the health of millions of people in need worldwide.

New data show that nearly one third (31%) of adults worldwide, approximately 1.8 billion people, did not meet the recommended levels of physical activity in 2022. The findings point to a worrying trend of physical inactivity among adults, which has increased by about 5 percentage points between 2010 and 2022. 

If the trend continues, levels of inactivity are projected to further rise to 35% by 2030, and the world is currently off track from meeting the global target to reduce physical inactivity by 2030. The World Health Organization (WHO) recommends that adults have 150 minutes of moderate-intensity, or 75 minutes of vigorous-intensity physical activity, or equivalent, per week. Physical inactivity puts adults at greater risk of cardiovascular diseases such as heart attacks and strokes, type 2 diabetes, dementia and cancers such as breast and colon.

The study was undertaken by researchers from WHO together with academic colleagues and published in The Lancet Global Health journal.

"These new findings highlight a lost opportunity to reduce cancer and heart disease, and to improve mental well-being through increased physical activity," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "We must renew our commitments to increasing levels of physical activity and prioritize bold action, including strengthened policies and increased funding, to reverse this worrying trend.”

The highest rates of physical inactivity were observed in the high-income Asia Pacific region (48%) and South Asia (45%), with levels of inactivity in other regions ranging from 28% in high-income Western countries to 14% in Oceania.

Of concern, disparities remain between gender and age. Physical inactivity is still more common among women globally compared with men, with inactivity rates of 34% compared to 29%. In some countries, this difference is as much as 20 percentage points. Additionally, people over 60 are less active than other adults, underscoring the importance of promoting physical activity for older adults.

“Physical inactivity is a silent threat to global health, contributing significantly to the burden of chronic diseases,” said Dr Rüdiger Krech, Director of Health Promotion at WHO. “We need to find innovative ways to motivate people to be more active, considering factors like age, environment, and cultural background. By making physical activity accessible, affordable, and enjoyable for all, we can significantly reduce the risk of noncommunicable diseases and create a population that is healthier and more productive.”

Despite the worrying results, there are some signs of improvement in some countries. The study showed that almost half of the world’s countries have made some improvements over the past decade, and 22 countries were identified as likely to reach the global target of reducing inactivity by 15% by 2030, if their trend continues at the same pace.

In light of these findings, WHO is calling on countries to strengthen their policy implementation to promote and enable physical activity through grassroots and community sport and active recreation and transport (walking, cycling and use of public transport), among other measures.

“Promoting physical activity goes beyond promoting individual lifestyle choice – it will require a whole-of-society approach and creating environments that make it easier and safer for everyone to be more active in ways they enjoy to reap the many health benefits of regular physical activity,” said Dr Fiona Bull, Head of the WHO Unit for Physical Activity.

Collective efforts based on partnerships between government and nongovernmental stakeholders and increased investments in innovative approaches will be needed to reach the least active people and to reduce inequalities in access to measures promoting and improving physical activity.

 

A new report from the World Health Organization (WHO) highlights that 2.6 million deaths per year were attributable to alcohol consumption, accounting for 4.7% of all deaths in that year, and 0.6 million deaths –to psychoactive drug use. Notably, 2 million of alcohol- and 0.4 million of drug-attributable deaths were among men.

The World Health Organization (WHO) issued a medical product alert on falsified semaglutides, the type of medicines that are used for treatment of type 2 diabetes and obesity in some countries.

The World Health Organization (WHO) congratulates Chad for having eliminated the gambiense form of human African trypanosomiasis, also known as sleeping sickness, as a public health problem. It marks the first neglected tropical disease to be eliminated in the country.

WHO remains concerned about the escalating health crisis in the occupied Palestinian territory, including the West Bank, where attacks on health infrastructure and increased restrictions on movement are obstructing access to health care. 

A spike in violence in the West Bank, including East Jerusalem, since the war in Gaza started has resulted in the deaths of 521 Palestinians, including 126 children between 7 October 2023 and 10 June 2024. In addition, over 5200 people, 800 of them children, have been injured, adding to the growing burden of trauma and emergency care at already strained health facilities.

As of 28 May, WHO has documented 480 attacks on health care in the West Bank since 7 October 2023, resulting in 16 deaths and 95 injuries. The attacks affected 54 health facilities, 20 mobile clinics and 319 ambulances. Fifty-nine percent of the attacks occurred in the cities of Tulkarem, Jenin and Nablus. They include attacks on health infrastructure and ambulances, detention of health workers and patients, obstruction of their access to health facilities, use of force on health workers and militarized searches of ambulances and staff.

The closure of checkpoints, arbitrary obstructions, and detentions of health workers, rising insecurity, as well as the siege and closure of entire towns and communities has made movement within the West Bank increasingly restricted, impeding access to health facilities. Extensive infrastructure and housing damage, particularly in the northern West Bank, have compounded the situation by obstructing access for ambulances and first-aid responders. 

The long-standing fiscal crisis faced by the Palestinian Authority (PA) is further impacting the health system and has been worsened by Israel’s increased withholding of tax revenues meant for the occupied Palestinian territory since 7 October, and the overall deterioration of the economic situation in occupied Palestinian territory. The impact of the financial situation on health service delivery is significant – with health workers receiving only half of their salary for nearly a year and 45% of essential medications being out of stock.  In most areas of the West Bank, primary care clinics and outpatient specialty clinics are now operating two days per week, and hospitals are operating at approximately 70% capacity.

Between October 2023 and May 2024, 44% of 28 292 applications for patients to seek medical care outside the West Bank, in East Jerusalem or Israeli health facilities, have been denied or remain pending with access being mainly granted to cancer, dialysis and other lifesaving cases. In the same period, 48% of the 26 562 companion permit applications have been denied or remain pending.

A comparison between October 2022–May 2023 and October 2023–May 2024 shows a 56% decrease in the West Bank patient permit applications and 22% decrease in approvals, and a 63% decrease in companion permit applications and a 24% decrease in approvals. Prior to October 2023, over 300 patients required permits daily to cross from the West Bank to east Jerusalem and Israeli health facilities.

WHO is supporting the Ministry of Health with procurement of essential medications as well as with technical assistance to address some of the policies and procedures that contribute to the fiscal crisis in health. Additionally, WHO has pre-positioned supplies at key hospitals across the West Bank, including in East Jerusalem, and conducted community trauma management training for first aid responders in the affected communities to boost emergency preparedness, but worsening insecurity and accessibility for emergency health workers and field volunteers to reach the injured, combined with the ongoing strict curfews, pose significant risks to the health system and make it very difficult for responders to reach those in need of urgent care.

WHO calls for the immediate and active protection of civilians and health care in the West Bank. International humanitarian law must be respected, which means the sanctity of health care must be observed at all times. 

The World Health Organization (WHO) today released its latest report on antibacterial agents, including antibiotics, in clinical and preclinical development worldwide. Although the number of antibacterial agents in the clinical pipeline increased from 80 in 2021 to 97 in 2023, there is a pressing need for new, innovative agents for serious infections and to replace those becoming ineffective due to widespread use.

First released in 2017, this annual report evaluates whether the current research and development (R&D) pipeline properly addresses infections caused by the drug-resistant bacteria most threatening to human health, as detailed in the 2024 WHO bacterial priority pathogen list (BPPL). Both documents aim to steer antibacterial R&D to better counter the ever-growing threat of antimicrobial resistance (AMR).

AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to medicines, making people sicker and increasing the risk of spread of infections that are difficult to treat, illness and deaths. AMR is driven largely by the misuse and overuse of antimicrobials, yet, at the same time, many people around the world do not have access to essential antimicrobial medicines.

“Antimicrobial resistance is only getting worse yet we’re not developing new trailblazing products fast enough to combat the most dangerous and deadly bacteria,” said Dr Yukiko Nakatani, WHO’s Assistant Director-General for Antimicrobial Resistance ad interim. “Innovation is badly lacking yet, even when new products are authorized, access is a serious challenge. Antibacterial agents are simply not reaching the patients who desperately need them, in countries of all income levels."

Not only are there too few antibacterials in the pipeline, given how long is needed for R&D and the likelihood of failure, there is also not enough innovation. Of the 32 antibiotics under development to address BPPL infections, only 12 can be considered innovative. Furthermore, just 4 of these 12 are active against at least 1 WHO ‘critical’ pathogen – critical being the BPPL’s top risk category, over ‘high’ and ‘medium’ priority. There are gaps across the entire pipeline, including in products for children, oral formulations more convenient for outpatients, and agents to tackle rising drug resistance.

Encouragingly, non-traditional biological agents, such as bacteriophages, antibodies, anti-virulence agents, immune-modulating agents and microbiome-modulating agents, are increasingly being explored as complements and alternatives to antibiotics. However, studying and regulating non-traditional agents is not straightforward. Further efforts are needed to facilitate clinical studies and assessments of these products, to help determine when and how to use these agents clinically.

Looking at newly approved antibacterials, since 1 July 2017, 13 new antibiotics have obtained marketing authorization but only 2 represent a new chemical class and can be termed innovative, underscoring the scientific and technical challenge in discovering novel antibacterials that are both effective against bacteria and safe for humans.

In addition, 3 non-traditional agents have been authorized, all are faecal-based products for restoring the gut microbiota, to prevent recurrent Clostridioides difficile infection (CDI) following antibiotic treatment in adults.

The preclinical pipeline is active and innovative, with many non-traditional approaches, as part of a stable number of preclinical candidates over the last 4 years. Its focus remains Gram-negative pathogens, which are resistant to last-resort antibiotics. Gram-negative bacteria have built-in abilities to find new ways to resist treatment and can pass along genetic material that allows other bacteria to become drug resistant as well.

The shift towards antibacterial agents targeting a single pathogen appears to have plateaued. Agents targeting a single pathogen increase the need for widely available and affordably priced rapid diagnostics, to ensure the relevant bacteria are present in the infections to be treated.

Greater transparency in the pipeline would: facilitate collaboration around potentially innovative but challenging projects, help scientists and drug developers, and generate more interest and funding for drug development for novel antibacterial agents.

Efforts to develop new antibacterial agents need to be accompanied by parallel efforts to ensure they can be equitably accessed, particularly in low- and middle-income countries. Universal access to quality and affordable tools for preventing, diagnosing and treating infections is key to mitigating AMR’s impact on public health and the economy, as per WHO’s Strategic and Operational Priorities for Addressing AMR in the Human Health Sector, the AMR resolution adopted by the 77th World Health Assembly and the People-centred approach to addressing AMR and core package of AMR interventions.

 

We, the Principals of the affected United Nations (UN) entities and international nongovernmental organizations (NGOs), call for the immediate and unconditional release of all personnel held in Yemen by the Houthi de facto authorities.

We are extremely concerned about the Houthi de facto authorities’ recent detention of 17 members of our organizations [UN entities and INGOs] and many others associated with civil society organizations, national and international NGOs, and other organizations supporting humanitarian activities.

These detentions are unprecedented – not only in Yemen but globally – and directly impede our ability to reach the most vulnerable people in Yemen, including the 18.2 million people who need humanitarian aid and protection.

We ask the de facto authorities to confirm the exact whereabouts of those detained and the conditions in which they are being held, as well as for immediate access to them.

International law prohibits the arbitrary deprivation of liberty. International Humanitarian Law requires all parties to armed conflict to respect and protect humanitarian personnel, including against harassment, mistreatment, and unlawful arrest or detention.

The targeting of humanitarian, human rights, and development workers in Yemen must stop. All those detained must be immediately released.

 

Signed by:

Achim Steiner, Administrator, UNDP

Amitabh Behar, Executive Director (interim), Oxfam International

Audrey Azoulay, Director-General, UNESCO

Catherine Russell, Executive Director, UNICEF

Cindy McCain, Executive Director, WFP

Inger Ashing, Chief Executive Officer, Save the Children International

Michelle Nunn, President and CEO, CARE

Tedros Adhanom Ghebreyesus, Director-General, WHO

Volker Türk, United Nations High Commissioner for Human Rights, OHCHR

Gavi, the Vaccine Alliance, in collaboration with partners, is announcing support for human rabies vaccines for post exposure prophylaxis (PEP) as part of routine immunisation. Eligible countries are receiving guidance on how to access these vaccines under Gavi’s cofinancing policy. The first round of applications will be reviewed in July 2024. Ninety-five percent of human rabies deaths occur in Africa and Asia, most often in marginalised communities that lack access to care.

The World Health Organization (WHO) is pleased to announce the appointment of Mr José Luis Castro as WHO Director-General Special Envoy for Chronic Respiratory Diseases. Chronic respiratory diseases (CRD), including asthma and chronic obstructive pulmonary disease (COPD), affect nearly half a billion people worldwide. Despite their significant impact, these diseases have often been overlooked in global health discussions, lacking the necessary recognition and resources.